LH

SEC source: 0001127602-22-003266 · form4.xml · nonDerivative · entry 2

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,262

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-003266 · form4.xml · nonDerivative · entry 1

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-031208 · form4.xml · nonDerivative · entry 4

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,252

SEC source: 0001127602-21-031208 · form4.xml · nonDerivative · entry 3

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,270

SEC source: 0001127602-21-031208 · form4.xml · nonDerivative · entry 2

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,295

SEC source: 0001127602-21-031208 · form4.xml · nonDerivative · entry 1

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,395

SEC source: 0001127602-22-003369 · form4.xml · nonDerivative · entry 3

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,762

SEC source: 0001127602-22-003369 · form4.xml · nonDerivative · entry 2

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,622

SEC source: 0001127602-22-003369 · form4.xml · nonDerivative · entry 1

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,967

F1 · balance_after: Amount reflects annuity payment of 432 shares made by the reporting person's grantor retained annuity trust to the reporting person on September 2, 2021.

SEC source: 0001127602-21-028661 · form4.xml · derivative · entry 3

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,098

Underlying: Common Stock · 2,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020.

F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-028661 · form4.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,181.5271

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 69.3574 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-028661 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,080.5271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 69.3574 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-028660 · form4.xml · derivative · entry 3

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,744

Underlying: Common Stock · 2,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020.

F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-028660 · form4.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,240.4989

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 123.1200 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-028660 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,139.4989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 123.1200 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-028239 · form4.xml · derivative · entry 3

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,341

Underlying: Common Stock · 2,007 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-028239 · form4.xml · nonDerivative · entry 2

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,409

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-028239 · form4.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-028238 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,212

Underlying: Common Stock · 9,024 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-028238 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,423

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-028238 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-028237 · form4.xml · derivative · entry 3

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,774

Underlying: Common Stock · 2,007 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-028237 · form4.xml · nonDerivative · entry 2

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,953

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-028237 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-025442 · form4.xml · derivative · entry 3

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires 2022-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan.

F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable.

SEC source: 0001127602-21-025442 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,264.7844

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · balance_after: Amount includes 27.7429 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-025442 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,764.7844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · balance_after: Amount includes 27.7429 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-21-022922 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,011.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-022922 · form4.xml · derivative · entry 3

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,617

Underlying: Common Stock · 50 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on August 1, 2021.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on August 1, 2021.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-022922 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,026.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-019484 · form4.xml · derivative · entry 3

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2022-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan.

F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable.

SEC source: 0001127602-21-019484 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,237.0415

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-21-019484 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,737.0415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-21-015959 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,844

SEC source: 0001127602-21-015391 · form4.xml · derivative · entry 3

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires 2021-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan.

F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable.

SEC source: 0001127602-21-015391 · form4.xml · nonDerivative · entry 2

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,569

F1 · price: The price of $269.1551 per share represents a weighted average of sales prices ranging from $269.06 to $269.291 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-21-015391 · form4.xml · nonDerivative · entry 1

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-013315 · form4.xml · derivative · entry 3

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,781

Underlying: Common Stock · 1,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units were part of a grant that vested in three equal annual installments beginning on April 3, 2019 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units were part of a grant that vested in three equal annual installments beginning on April 3, 2019 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-21-013315 · form4.xml · nonDerivative · entry 2

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,344

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-013315 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-21-012469 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,006.3789

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-21-012468 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,237.0415

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-21-012365 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,433

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-012365 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,028

F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020.

SEC source: 0001127602-21-012363 · form4.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,001.1697

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-012363 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,080.1697

F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020.

SEC source: 0001127602-21-012364 · form4.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,186

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-012364 · form4.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,265

F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020.

SEC source: 0001127602-21-012362 · form4.xml · nonDerivative · entry 2

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,786

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-21-012362 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,576

F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020.